Belgian company Omega Pharma says its 2008 net profit grew 19% year-on-year to 50.8 million euros ($66.0 million), rising to 66.4 million euros after addition of 24% of the net income of its health care supplies affiliate Arseus.
The firm, which is one of the few major players in its sector that deals exclusively in over-the-counter products, says net turnover rose 3% to 811.2 million euros, as its operating cash flow jumped 4% to 130.1 million euros.
Earnings before interest, taxes, depreciation and amortization in its home market soared 26% to 29.7 million euros on the back of a 3% rise in turnover to 205.0 million euros. This corresponds to a 14.5% EBITDA margin versus 11.9% in 2007, thanks to restructurings and the increase efficiency of its domestic operations. However, EBITDA in France fell 8% to 19.4 million euros, as revenues dropped 2% to 187.4 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze